Elevation Historical Income Statement

ELEV Stock

USD 0.64 0.02 3.23%

Historical analysis of Elevation Oncology income statement accounts such as Selling General Administrative of 9.2 M or Selling And Marketing Expenses of 33.3 K can show how well Elevation Oncology performed in making a profits. Evaluating Elevation Oncology income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Elevation Oncology's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Elevation Oncology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Elevation Oncology is a good buy for the upcoming year.

Net Income Gross Profit

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Elevation Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For more information on how to buy Elevation Stock please use our How to Invest in Elevation Oncology guide.

About Elevation Income Statement Analysis

Elevation Oncology Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Elevation Oncology shareholders. The income statement also shows Elevation investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Elevation Oncology Income Statement Chart

At this time, Elevation Oncology's Interest Expense is fairly stable compared to the past year. Research Development is likely to climb to about 32.7 M in 2024, whereas Selling General Administrative is likely to drop slightly above 9.2 M in 2024.

Selling General Administrative Selling And Marketing Expenses Research Development

Most accounts from Elevation Oncology's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Elevation Oncology current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Elevation Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For more information on how to buy Elevation Stock please use our How to Invest in Elevation Oncology guide.At this time, Elevation Oncology's Interest Expense is fairly stable compared to the past year. Research Development is likely to climb to about 32.7 M in 2024, whereas Selling General Administrative is likely to drop slightly above 9.2 M in 2024.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	18K	27K	39K	27.2K
Cost Of Revenue	18K	27K	39K	27.2K

Reconciled Depreciation Cost Of Revenue

Elevation Oncology income statement Correlations

	Depreciation And Amortization	Selling General Administrative	Selling And Marketing Expenses	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Gross Profit	Net Income From Continuing Ops	Cost Of Revenue	Reconciled Depreciation	Net Interest Income	Interest Income	Non Operating Income Net Other
Depreciation And Amortization		-0.83	1.0	-0.79	0.79	0.75	-0.74	0.78	-0.79	0.79	-1.0	0.79	0.37	0.71	0.73	-0.7	-0.7	-0.55	-0.53	-0.53
Selling General Administrative	-0.83		-0.83	0.93	-0.94	-0.91	0.87	-0.92	0.93	-0.94	0.81	-0.94	0.08	-0.82	-0.94	0.9	0.9	0.62	0.64	0.64
Selling And Marketing Expenses	1.0	-0.83		-0.79	0.79	0.75	-0.73	0.78	-0.79	0.79	-1.0	0.79	0.37	0.71	0.73	-0.71	-0.71	-0.56	-0.54	-0.53
Other Operating Expenses	-0.79	0.93	-0.79		-1.0	-1.0	0.99	-1.0	1.0	-1.0	0.76	-1.0	0.09	-0.69	-0.98	0.74	0.74	0.4	0.39	0.39
Operating Income	0.79	-0.94	0.79	-1.0		1.0	-0.99	1.0	-1.0	1.0	-0.77	1.0	-0.1	0.71	0.99	-0.75	-0.75	-0.43	-0.41	-0.4
Ebit	0.75	-0.91	0.75	-1.0	1.0		-0.99	1.0	-1.0	1.0	-0.72	1.0	-0.11	0.66	0.98	-0.71	-0.71	-0.36	-0.34	-0.34
Research Development	-0.74	0.87	-0.73	0.99	-0.99	-0.99		-0.99	0.99	-0.99	0.71	-0.99	0.07	-0.6	-0.96	0.63	0.63	0.28	0.25	0.25
Ebitda	0.78	-0.92	0.78	-1.0	1.0	1.0	-0.99		-1.0	1.0	-0.75	1.0	-0.08	0.68	0.98	-0.72	-0.72	-0.38	-0.36	-0.36
Total Operating Expenses	-0.79	0.93	-0.79	1.0	-1.0	-1.0	0.99	-1.0		-1.0	0.76	-1.0	0.09	-0.69	-0.98	0.74	0.74	0.4	0.39	0.39
Income Before Tax	0.79	-0.94	0.79	-1.0	1.0	1.0	-0.99	1.0	-1.0		-0.77	1.0	-0.1	0.71	0.99	-0.75	-0.75	-0.43	-0.41	-0.4
Total Other Income Expense Net	-1.0	0.81	-1.0	0.76	-0.77	-0.72	0.71	-0.75	0.76	-0.77		-0.77	-0.4	-0.69	-0.7	0.69	0.69	0.55	0.53	0.52
Net Income	0.79	-0.94	0.79	-1.0	1.0	1.0	-0.99	1.0	-1.0	1.0	-0.77		-0.1	0.71	0.99	-0.75	-0.75	-0.43	-0.41	-0.4
Income Tax Expense	0.37	0.08	0.37	0.09	-0.1	-0.11	0.07	-0.08	0.09	-0.1	-0.4	-0.1		-0.32	-0.25	0.29	0.29	0.32	0.31	0.3
Gross Profit	0.71	-0.82	0.71	-0.69	0.71	0.66	-0.6	0.68	-0.69	0.71	-0.69	0.71	-0.32		0.78	-0.93	-0.93	-0.93	-0.89	-0.88
Net Income From Continuing Ops	0.73	-0.94	0.73	-0.98	0.99	0.98	-0.96	0.98	-0.98	0.99	-0.7	0.99	-0.25	0.78		-0.8	-0.8	-0.51	-0.49	-0.48
Cost Of Revenue	-0.7	0.9	-0.71	0.74	-0.75	-0.71	0.63	-0.72	0.74	-0.75	0.69	-0.75	0.29	-0.93	-0.8		1.0	0.85	0.9	0.9
Reconciled Depreciation	-0.7	0.9	-0.71	0.74	-0.75	-0.71	0.63	-0.72	0.74	-0.75	0.69	-0.75	0.29	-0.93	-0.8	1.0		0.85	0.9	0.9
Net Interest Income	-0.55	0.62	-0.56	0.4	-0.43	-0.36	0.28	-0.38	0.4	-0.43	0.55	-0.43	0.32	-0.93	-0.51	0.85	0.85		0.97	0.97
Interest Income	-0.53	0.64	-0.54	0.39	-0.41	-0.34	0.25	-0.36	0.39	-0.41	0.53	-0.41	0.31	-0.89	-0.49	0.9	0.9	0.97		1.0
Non Operating Income Net Other	-0.53	0.64	-0.53	0.39	-0.4	-0.34	0.25	-0.36	0.39	-0.4	0.52	-0.4	0.3	-0.88	-0.48	0.9	0.9	0.97	1.0

Click cells to compare fundamentals

Elevation Oncology Account Relationship Matchups

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Elevation Stock Analysis

When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Elevation Historical Income Statement

About Elevation Income Statement Analysis

Elevation Oncology Income Statement Chart

Elevation Oncology income statement Correlations

Elevation Oncology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Elevation Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Depreciation And Amortization	Interest Expense
Selling General Administrative	Selling And Marketing Expenses
Other Operating Expenses	Operating Income
Ebit	Research Development
Ebitda	Total Operating Expenses
Income Before Tax	Total Other Income Expense Net
Net Income Applicable To Common Shares	Net Income
Income Tax Expense	Total Revenue
Gross Profit	Net Income From Continuing Ops
Cost Of Revenue	Reconciled Depreciation
Tax Provision	Net Interest Income
Interest Income	Non Operating Income Net Other

Selling And Marketing Expenses	+ 1.0	Depreciation And Amortization
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income

Net Income	- 1.0	Total Operating Expenses
Income Before Tax	- 1.0	Total Operating Expenses
Total Operating Expenses	- 1.0	Ebitda
Total Operating Expenses	- 1.0	Ebit
Total Operating Expenses	- 1.0	Operating Income
Net Income	- 1.0	Other Operating Expenses